Skip to main content

Alpine Immune Sciences — Company Overview, News & Financial Data

Alpine Immune Sciences logo
Alpine Immune Sciences
Alpine Immune Sciences primary media
Company profile

Alpine Immune Sciences

About

Alpine Immune Sciences (NASDAQ:ALPN) is a biotechnology company focused on discovering and developing innovative therapies to modulate the immune system, targeting cancer, autoimmune disorders, and other diseases. With a versatile platform, Alpine is advancing a pipeline of unique candidates designed to engage the immune system through multiple mechanisms. The company's projects leverage its proprietary technologies to create potentially transformative treatments that aim to improve patient outcomes significantly. Alpine Immune Sciences is committed to pushing the boundaries of immunotherapy, striving for breakthroughs that can address unmet medical needs and improve the lives of patients worldwide.

Snapshot

2007Year founded
141Employees
Seattle, United StatesHead office
Loading Map...
Global footprint

Operations

All Locations
Seattle, US

Products and/or services of Alpine Immune Sciences

  • ALPN-101, a dual ICOS/CD28 antagonist in development for inflammatory and autoimmune diseases.
  • ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor aimed at cancer treatment.
  • ALPN-303, a dual BAFF/APRIL antagonist for B cell mediated diseases.
  • Partnership with AbbVie to develop and commercialize ALPN-101, leveraging AbbVie's global resources for advancement.
  • Collaborations with Adaptimmune for next-generation T-cell therapies, enhancing the effectiveness of cancer immunotherapy.
  • Research and licensing agreement with Kite Pharma to discover and develop protein-based therapeutics for oncology applications.

Alpine Immune Sciences executive team

  • Dr. Mitchell H. Gold M.D.Executive Chairman & CEO
  • Dr. Stanford Peng M.D., Ph.D.President and Head of Research & Development
  • Mr. Paul RickeySenior VP, CFO, Treasurer & Secretary
  • Ms. M. Christina YiChief Technology Officer
  • Temre JohnsonHead of IR & Corporate Communications
  • Dr. Remy Durand Ph.D.Chief Business Officer
  • Dr. Wolfgang Dummer M.D., Ph.D.Chief Medical Officer

GET YOUR GRAFA EDGE NOW

We'll switch on a 30-day Edge trial as a welcome gift